1
Quattropani Anna, Rueckle Thomas, Schwarz Matthias, Dorbais Jerôme, Sauer Wolfgang, Cleva Christophe, Desforges Gwénaëlle: Thiazole derivatives and use thereof. Applied Research Systems Ars Holding, Quattropani Anna, Rueckle Thomas, Schwarz Matthias, Dorbais Jerôme, Sauer Wolfgang, Cleva Christophe, Desforges Gwénaëlle, HASSA Juergen, July 28, 2005: WO/2005/068444 (17 worldwide citation)

The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, ...


2
Abel Ulrich, Deppe Holger, Feurer Achim, Grädler Ulrich, Goutopoulos Andreas, Schwarz Matthias: Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders. Laboratoires Serono, Abel Ulrich, Deppe Holger, Feurer Achim, Grädler Ulrich, Goutopoulos Andreas, Schwarz Matthias, ZIMMER Franz Josef, June 1, 2006: WO/2006/056427 (15 worldwide citation)

The invention provides novel, substituted 4-arylamino pyridone compounds (formula (I)), pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R 1, R2, R9, R 10, R 11, R 12, R 13, R 14 and L are as defined in the specification. Such compounds are MEK inhibitors and use ...


3
Abel Ulrich, Deppe Holger, Feurer Achim, Grädler Ulrich, Otte Kerstin, Sekul Renate, Thiemann Meinolf, Goutopoulos Andreas, Schwarz Matthias, Jiang Xuliang: 3-arylamino pyridine derivatives. Applied Research Systems Ars Holding, Abel Ulrich, Deppe Holger, Feurer Achim, Grädler Ulrich, Otte Kerstin, Sekul Renate, Thiemann Meinolf, Goutopoulos Andreas, Schwarz Matthias, Jiang Xuliang, GOLDBACH Klara, May 4, 2006: WO/2006/045514 (11 worldwide citation)

The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of ...


4
Page Patrick, Jorand Lebrun Catherine, Thomas Russell J, Schwarz Matthias: Piperazine-2-carboxamide derivatives. Applied Research Systems Ars Holding, Page Patrick, Jorand Lebrun Catherine, Thomas Russell J, Schwarz Matthias, PLEBANI Rinaldo, August 26, 2004: WO/2004/071390 (11 worldwide citation)

The present invention is related to piperazine -2-carboxamide derivatives of formula (I) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. Wherein A, X, Y, R1 and R2 are as defined in the description.


5
Goutopoulos Andreas, Askew Jr Benny C, Diep Nhut Kiet, Karra Srinivasa, Schwarz Matthias, Yu Henry: Novel arylamino n-heteraryls as mek inhibitors. Laboratoires Serono, Goutopoulos Andreas, Askew Jr Benny C, Diep Nhut Kiet, Karra Srinivasa, Schwarz Matthias, Yu Henry, DAVIS Steven G, November 1, 2007: WO/2007/123939 (10 worldwide citation)

The invention provides novel arylamino N-heteroaryl MEK inhibitors of Formula (I): Such compounds are MEK inhibitors that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation. Also disclosed. is the treatment of a hyperproliferative disease in mammals, and phar ...


6
Schwarz Matthias, Sebille Eric, Cleva Christophe, Merlot Cedric, Church Dennis, Page Patrick, Macritchie Jacqueline A, Atherall John Frederick, Crosignani Stefano, Pupowicz Doris: Tricyclic spiro derivatives as crth2 modulators. Laboratoires Serono, Schwarz Matthias, Sebille Eric, Cleva Christophe, Merlot Cedric, Church Dennis, Page Patrick, Macritchie Jacqueline A, Atherall John Frederick, Crosignani Stefano, Pupowicz Doris, MERCK SERONO INTERNATIONAL INTELLECTUAL PROPERTY, November 30, 2006: WO/2006/125784 (9 worldwide citation)

The present invention is related to the use of spiro derivatives of Formula (I) for the treatment and/or prevention of allergic diseases, inflammatory dermatoses and other diseases with an inflammatory component. Specifically, the present invention is related to the use of spiro derivatives for the ...


7
Page Patrick, Schwarz Matthias, Sebille Eric, Cleva Christophe, Merlot Cedric, Maio Maurizio: 2,3 substituted pyrazine sulfonamides as inhibitors of crth2. Laboratoires Serono, Page Patrick, Schwarz Matthias, Sebille Eric, Cleva Christophe, Merlot Cedric, Maio Maurizio, MERCK SERONO INTERNATIONAL INTELLECTUAL PROPERTY, October 26, 2006: WO/2006/111560 (8 worldwide citation)

The present invention is related to the use of 2,3 substituted pyrazine sulfonamides of formula (I) for the treatment and/or prevention of allergic diseases, inflammatory dermatoses and other diseases with an inflammatory component. Specifically, the present invention is related to the use of 2,3 su ...


8
Bombrun Agnes, Schwarz Matthias, Crosignani Stefano, Covini David, Marin Delphine: (s1p) Receptor for the treatment of multiple sclerosis. Merck Serono, Bombrun Agnes, Schwarz Matthias, Crosignani Stefano, Covini David, Marin Delphine, MERCK SERONO GENEVA, February 12, 2009: WO/2009/019167 (6 worldwide citation)

The invention relates to compounds of formula (I): wherein X, W, Q, R, R1 and R2 have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.


9
Magar Sharad, Goutopoulos Andreas, Liao Yihua, Schwarz Matthias, Russell Thomas J: Piperazine derivatives and methods of use. Applied Research Systems Ars Holding, Magar Sharad, Goutopoulos Andreas, Liao Yihua, Schwarz Matthias, Russell Thomas J, SERONO INTERNATIONAL INTELLECTUAL PROPERTY, April 15, 2004: WO/2004/031182 (5 worldwide citation)

The invention provides 2-carboxamide piperazine compounds of formula I, R3 . I N\ ' N ˜` R2 I(0)z- o R4 I wherein R', R2, R3 and R4 are as defined in the claims and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the i ...


10
Ostgard Daniel, Berweiler Monika, Göttlinger Markus, Laporte Steffen, Schwarz Matthias: Activated base metal catalysts. Evonik Degussa, Ostgard Daniel, Berweiler Monika, Göttlinger Markus, Laporte Steffen, Schwarz Matthias, EVONIK DEGUSSA, December 4, 2008: WO/2008/145179 (5 worldwide citation)

Nitro-compounds are hydrogenated with an activated Ni catalyst that has an average particle size (APS) less than 25 µm and is doped with one or more elements from the list of Mg, Ce, Ti, V, Nb, Cr, W, Mn, Re, Fe, Ru, Co, Rh, Ir, Pt, Cu, Ag, Au and Bi via its/their addition to the alloy before activa ...